Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
9.45
-0.09 (-0.94%)
Nov 13, 2026, 4:00 PM EST - Market closed
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 298 employees as of December 31, 2025. The number of employees increased by 28 or 10.37% compared to the previous year. That makes Syndax Pharmaceuticals the 23,920th largest employer in the world and 3,066th in the United States.
Employees
298
Change (1Y)
28
Growth (1Y)
10.37%
Revenue / Employee
$972,074
Profits / Employee
-$702,963
Market Cap
850.77M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 298 | 28 | 10.37% | 298 | 0 |
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| Pharming Group | 407 |
| MeiraGTx Holdings | 386 |
| Monte Rosa Therapeutics | 185 |
| Rigel Pharmaceuticals | 174 |
| ORIC Pharmaceuticals | 111 |
| Inventiva | 87 |
| Corvus Pharmaceuticals | 37 |
SNDX News
- 3 days ago - Syndax Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 5 days ago - Syndax Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 6 days ago - Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Syndax selloff yesterday an overreaction, says H.C. Wainwright - TheFly
- 11 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 - GlobeNewsWire
- 11 days ago - Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 - GlobeNewsWire
- 12 days ago - Syndax price target lowered to $36 from $38 at H.C. Wainwright - TheFly